Trial Profile
Randomized Study on the Efficacy and Safety of Landiolol, an Ultra-Short-Acting beta 1-Adrenergic Blocker, in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2012
Price :
$35
*
At a glance
- Drugs Landiolol (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 13 Jan 2012 New trial record
- 10 Dec 2011 Results published in the Circulation Journal.